Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2) - Zhao, Wan-Hong; Wang, Bai-Yan; Chen, Li-Juan; Fu, Wei-Jun; Xu, Jie; Liu, Jie; Jin, Shi-Wei; Chen, Yin-Xia; Cao, Xing-Mei; Yang, Yun; Zhang, Yi-Lin; Wang, Fang-Xia; et al. (Journal of hematology and oncology, 2022)
Keywords: Antibodies; Antigens; B cell maturation antigen; Cancer therapies; Central nervous system; Chemotherapy; Chimeric antigen receptor therapy; Chimeric antigen receptors; Cyclophosphamide; Cytokines; Diseases; Drug dosages; Drug resistance; Efficacy; Fludarabine; Hematology; Hepatitis B; Infections; Lung cancer; Lymphocytes; Lymphocytes T; Multiple myeloma; Oncology; Patients; Relapse; Safety; Stem cell transplantation; Toxicity; Virus diseases; China